Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05406700 · ClinicalTrials.gov registry record · Early Phase 1
Niraparib In Recurrent IDH 1/2 Gliomas
A Early Phase 1 study of Low Grade Glioma and Glioma, Malignant, sponsored by Massachusetts General Hospital.
- Active
- Registry status
- Early Phase 1
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT05406700: Active Early Phase 1 study of Low Grade Glioma and Glioma, Malignant, sponsored by Massachusetts General Hospital.
NCT05406700 is a Early Phase 1 study of Low Grade Glioma and Glioma, Malignant that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 16 participants, below the 113-participant average among 23 other Low Grade Glioma trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05406700, a Early Phase 1 study of Low Grade Glioma and Glioma, Malignant, is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a randomized, two-arm, open-label, phase 0 trial to assess intratumoral pharmacokinetics and pharmacodynamics of niraparib in subjects with progressive IDH1 or IDH2 mutant glioma. \- This research study involves an experimental treatment called Niraparib.
Primary Outcome
Drug concentrations of niraparib in enhancing and non-enhancing tumor tissue from subjects treated with the agent for one month prior to surgery.
Conditions Studied
Interventions
- DRUG Niraparib
- DRUG Resection/Treatment with Niraparib
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2023-05-18 |
| Est. Completion | 2026-10 |
| Phase | Early Phase 1 |
What the registry record for NCT05406700 still lists
NCT05406700 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 113-participant average among 23 other Low Grade Glioma trials with a reported enrollment target (86% lower).
The record links to 5 conditions, with Low Grade Glioma appearing as the primary indexed condition, and to 2 interventions - of which Niraparib is the first listed.
NCT05406700 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05406700 about?
NCT05406700 is a clinical study titled "Niraparib In Recurrent IDH 1/2 Gliomas". This is a randomized, two-arm, open-label, phase 0 trial to assess intratumoral pharmacokinetics and pharmacodynamics of niraparib in subjects with progressive IDH1 or IDH2 mutant glioma. \- This research study involves an experimental treatment called Niraparib.
What is the current status of trial NCT05406700?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 16 participants. The study started on 2023-05-18. Estimated completion is 2026-10.
What conditions does trial NCT05406700 study?
This clinical trial studies the following conditions: Low Grade Glioma, Glioma, Malignant, Recurrent Glioma, IDH1 Mutation, IDH2 Gene Mutation.
What interventions are being tested in trial NCT05406700?
The interventions under investigation include: Niraparib (DRUG), Resection/Treatment with Niraparib (DRUG).
Who is sponsoring clinical trial NCT05406700?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05406700 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Low Grade Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05406700's enrollment target sits among peer trials
16 24th of 23 the lowest of 23 other Low Grade Glioma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Low Grade Glioma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of 18F-Fluciclovine Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) in LGG
RECRUITING · Early Phase 1
-
A Vaccine Trial for Low Grade Gliomas
RECRUITING · Phase 2
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas
RECRUITING · Phase 1
-
Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial
RECRUITING · Phase 2
-
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI